Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity

BMC Genomics

Rong Stephanie Huang²  Nancy J Cox¹  Dana Ziliak²  Paul Geeleher²  Hae Kyung Im³  Divya Lenkala²  Eric R Gamazon¹  Bonnie LaCroix² 

[1] Section of Genetic Medicine, Department of Medicine, Chicago, IL, 60637, USA;Section of Hematology/Oncology, Department of Medicine, University of Chicago, 900 E 57th street, KCBD room 7148, Chicago, IL, 60637, USA;Department of Health Studies, The University of Chicago, Chicago, IL, 60637, USA

关键词: HapMap;    Platinum;    SNP;    Gene expression;    microRNA;   

Others  :  1217454
DOI  :  10.1186/1471-2164-15-292

 received in 2014-02-11, accepted in 2014-04-09,  发布年份 2014

【 摘 要 】

Background

Using genome-wide genetic, gene expression, and microRNA expression (miRNA) data, we developed an integrative approach to investigate the genetic and epigenetic basis of chemotherapeutic sensitivity.

Results

Through a sequential multi-stage framework, we identified genes and miRNAs whose expression correlated with platinum sensitivity, mapped these to genomic loci as quantitative trait loci (QTLs), and evaluated the associations between these QTLs and platinum sensitivity. A permutation analysis showed that top findings from our approach have a much lower false discovery rate compared to those from a traditional GWAS of drug sensitivity. Our approach identified five SNPs associated with 10 miRNAs and the expression level of 15 genes, all of which were associated with carboplatin sensitivity. Of particular interest was one SNP (rs11138019), which was associated with the expression of both miR-30d and the gene ABCD2, which were themselves correlated with both carboplatin and cisplatin drug-specific phenotype in the HapMap samples. Functional study found that knocking down ABCD2 in vitro led to increased apoptosis in ovarian cancer cell line SKOV3 after cisplatin treatment. Over-expression of miR-30d in vitro caused a decrease in ABCD2 expression, suggesting a functional relationship between the two.

Conclusions

We developed an integrative approach to the investigation of the genetic and epigenetic basis of human complex traits. Our approach outperformed standard GWAS and provided hints at potential biological function. The relationships between ABCD2 and miR-30d, and ABCD2 and platin sensitivity were experimentally validated, suggesting a functional role of ABCD2 and miR-30d in sensitivity to platinating agents.

【 授权许可】

   
2014 LaCroix et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Williams C, Whitehouse J: Cis-platinum: a new anticancer agent. Br Med J 1979, 1:1689-1691. June 23
• [2]Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23.
• [3]Bellmunt J, Pons F, Orsola A: Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr Opin Urol 2013, 23:466-471.
• [4]Gamazon ER, Huang RS, Cox NJ, Dolan ME: Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 2010, 107:9287-9292.
• [5]Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ: Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010, 6:e1000888.
• [6]Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005, 37:766-770.
• [7]Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
• [8]Di Leva G, Garofalo M, Croce CM: MicroRNAs in cancer. Annu Rev Pathol 2013, 9:287-314.
• [9]Im HK, Gamazon ER, Stark AL, Huang RS, Cox NJ, Dolan ME: Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet 2012, 8:e1002525.
• [10]Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME: Genetic architecture of transcript-level variation in humans. Am J Hum Genet 2008, 82:1101-1113.
• [11]Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, Montgomery S, Tavaré S, Deloukas P, Dermitzakis ET: Population genomics of human gene expression. Nat Genet 2007, 39:1217-1224.
• [12]Gamazon ER, Ziliak D, Im HK, LaCroix B, Park DS, Cox NJ, Huang RS: Genetic Architecture of MicroRNA Expression: Implications for the Transcriptome and Complex Traits. Am J Hum Genet 2012, 90:1-18. AOP
• [13]Ziliak D, Gamazon ER, Lacroix B, Im HK, Wen Y, Huang RS: Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility. Mol Cancer Ther 2012, 11:2054-2061.
• [14]Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, Schweitzer AC, Blume JE, Dolan ME: Identification of genetic variants contributing to cisplatin-induced cytotoxicity using a genome-wide approach. Am J Hum Genet 2007, 81:427-437.
• [15]Stegle O, Parts L, Piipari M, Winn J, Durbin R: Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc 2012, 7:500-507.
• [16]Storey JD, Tibshirani R: Statistical significance for genome-wide studies. Proc Natl Acad Sci U S A 2003, 100:9440-9445.
• [17]Gamazon ER, Huang RS, Dolan ME, Cox NJ, Im HK: Integrative genomics: quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data. Front Genet 2012, 3(May):202.
• [18]Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME: Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther 2007, 6:31-36.
• [19]Wheeler HE, Gamazon ER, Stark AL, O’Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME: Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2011, 13:35-43.
• [20]Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ: PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics 2010, 20:269-273.
• [21]Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME: Population differences in microRNA expression and biological implications. RNA Biol 2011, 8:692-701.
• [22]Gamazon ER, Huang RS, Cox NJ: SCAN: a systems biology approach to pharmacogenomic discovery. Methods Mol Biol 2013, 1015:213-224.
• [23]Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, Dolan ME, Cox NJ: SCAN: SNP and copy number annotation. Bioinformatics 2010, 26:259-262.
• [24]Yang X, Zhong X, Tanyi JL, Shen J, Xu C, Gao P, Zheng TM, DeMichele A, Zhang L: mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells. Biochem Biophys Res Commun 2013, 431:617-622.
• [25]Kumar M, Lu Z, Takwi AAL, Chen W, Callander NS, Ramos KS, Young KH, Li Y: Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011, 30:843-853.
• [26]Li N, Kaur S, Greshock J, Lassus H, Zhong X, Wang Y, Leminen A, Shao Z, Hu X, Liang S, Katsaros D, Huang Q, Bützow R, Weber BL, Coukos G, Zhang L: A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res 2012, 72:154-164.
• [27]Kobayashi N, Uemura H, Nagahama K, Okudela K: Identification of miR-30d as a novel prognostic maker of prostate. Cancer 2012, 3:1455-1471.
• [28]Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, Osman I, Hernando E: miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011, 20:104-118.
• [29]Takano H, Koike R, Onodera O, Tsuji S: Mutational analysis of X-linked adrenoleukodystrophy gene. Cell Biochem Biophys 2000, 32:177-185. Spring
• [30]Maier EM, Mayerhofer PU, Asheuer M, Köhler W, Rothe M, Muntau AC, Roscher AA, Holzinger A, Aubourg P, Berger J: X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. Biochem Biophys Res Commun 2008, 377:176-180.
• [31]Gloeckner CJ, Mayerhofer PU, Landgraf P, Muntau AC, Holzinger A, Gerber JK, Kammerer S, Adamski J, Roscher AA: Human adrenoleukodystrophy protein and related peroxisomal ABC transporters interact with the peroxisomal assembly protein PEX19p. Biochem Biophys Res Commun 2000, 271:144-150.
• [32]Park C-Y, Kim H-S, Jang J, Lee H, Lee JS, Yoo J-E, Lee DR, Kim D-W: ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy. PLoS One 2013, 8:e56242.
• [33]Gillet J-P, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM: Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm 2011, 8:2080-2088.